Why Is INSMED INC (INSM) Stock Up Today?

Why INSM stock is up today

INSM stock surged 31.53% to $130.24 in a single session driven by a combination of raised revenue guidance and strong Q2 2026 performance. The company announced a significant increase in its revenue forecast for BRINSUPRI (brensocatib) and highlighted robust sales growth. The stock opened with a modest 1.5% gap up and climbed steadily throughout the session, reaching an intraday high of $137.70 before settling near $130.16.

What Happened

The sharp rise in INSM shares came after Insmed reported a standout second quarter with 296% revenue growth and raised its revenue guidance for BRINSUPRI. The company now forecasts $1.25 billion to $1.40 billion in BRINSUPRI sales, up from previous estimates. Insmed also raised its peak sales outlook for its three lead programs to more than $14 billion. Jefferies upgraded the stock, raising its price target to $175 from $160. The Q2 2026 earnings call highlighted progress in the company’s respiratory therapies and strong performance across its pipeline.

What The Data Shows

The stock opened at $100.47 and traded as high as $137.70 during the session. Volume reached 6.9 million shares, more than double the 3-month daily average. Over the last 8 sessions, the stock has risen 25.5%, from $104.13 to $130.71. Unusual options activity was noted, with $2.3 million in call premium versus $581,000 in put premium, including a notable $1.6 million print. In the last 90 days, insiders have sold 18 times, totaling $16.4 million, with no buys recorded.

What To Watch

The company’s Q2 2026 earnings call on August 6, 2026, provided key insights but no upcoming earnings date is scheduled. Investors will want to monitor the breadth of coverage and any further updates on BRINSUPRI’s performance or additional guidance from the company.